|
Name |
12-hydroxyl zygosporin G
|
Molecular Formula | C30H37NO6 | |
IUPAC Name* |
[16-benzyl-5-hydroxy-13-(hydroxymethyl)-5,7,14-trimethyl-6,18-dioxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-trien-2-yl]acetate
|
|
SMILES |
CC(=O)OC1C=CC(C)(O)C(=O)C(C)CC=CC2C=C(CO)C(C)C3C(Cc4ccccc4)NC(=O)C213
|
|
InChI |
InChI=1S/C30H37NO6/c1-18-9-8-12-23-16-22(17-32)19(2)26-24(15-21-10-6-5-7-11-21)31-28(35)30(23,26)25(37-20(3)33)13-14-29(4,36)27(18)34/h5-8,10-14,16,18-19,23-26,32,36H,9,15,17H2,1-4H3,(H,31,35)/b12-8+,14-13+/t18-,19+,23-,24-,25+,26-,29+,30+/m0/s1
|
|
InChIKey |
XTNPATOXKYCHLM-FNXBMICLSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 507.63 | ALogp: | 2.9 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 112.9 | Aromatic Rings: | 4 |
Heavy Atoms: | 37 | QED Weighted: | 0.423 |
Caco-2 Permeability: | -4.802 | MDCK Permeability: | 0.00003490 |
Pgp-inhibitor: | 0.271 | Pgp-substrate: | 0.012 |
Human Intestinal Absorption (HIA): | 0.19 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.942 | Plasma Protein Binding (PPB): | 90.87% |
Volume Distribution (VD): | 1.63 | Fu: | 12.65% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.107 |
CYP2C19-inhibitor: | 0.098 | CYP2C19-substrate: | 0.461 |
CYP2C9-inhibitor: | 0.09 | CYP2C9-substrate: | 0.084 |
CYP2D6-inhibitor: | 0.035 | CYP2D6-substrate: | 0.078 |
CYP3A4-inhibitor: | 0.942 | CYP3A4-substrate: | 0.607 |
Clearance (CL): | 2.45 | Half-life (T1/2): | 0.161 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.041 |
Drug-inuced Liver Injury (DILI): | 0.974 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.867 | Maximum Recommended Daily Dose: | 0.566 |
Skin Sensitization: | 0.031 | Carcinogencity: | 0.424 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.008 |
Respiratory Toxicity: | 0.963 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004444 | 0.861 | D01TSI | 0.278 | ||||
ENC004026 | 0.765 | D06CWH | 0.272 | ||||
ENC004542 | 0.703 | D0V3ZA | 0.271 | ||||
ENC001922 | 0.701 | D0SP3D | 0.270 | ||||
ENC002202 | 0.700 | D0E9KA | 0.269 | ||||
ENC004463 | 0.692 | D09NNH | 0.264 | ||||
ENC005440 | 0.689 | D0W7RJ | 0.259 | ||||
ENC005439 | 0.686 | D0A5LH | 0.253 | ||||
ENC005441 | 0.631 | D0D7KC | 0.252 | ||||
ENC004468 | 0.621 | D0TB8C | 0.252 |